chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On 3/24/02, the vaccinee received her 1st injection of Engerix-B. On 3/26/02, 2 days post immunization, she experienced nausea. The nausea persisted on 3/27/02. Follow up on 01/16/04: "The subject's medical history included a "very mild form" of sickle cell disease diagnosed in 1984.  The physician reported, "usually she is stable without any symptoms."  There were no concurrent medications.  On 03/25/02, the subject received her first injection of Engerix-B (Lot # ENG5262A4).  On 03/26/02, she developed a rash.  The physician made a diagnosis of allergic reaction and considered it to be related to Engerix-B administration.  The allergic reaction resolved on 03/28/03.  The subject received her second injection of Engerix-B on an unspecified date.  No adverse experiences were reported.  On 10/09/02, the subject received her third injection of Engerix-B (Lot # ENG5303A4).  "A few hours" post-immunization, she developed "severe" nausea and emesis.  The physician made a diagnosis of allergic reaction and considered it to be related to Engerix-B administration. The second allergic reaction resolved on 10/13/02.
Admission Date: 10/9/2022 Discharge Date: 10/12/2022  PRESENTING PROBLEM: Sepsis   HOSPITAL COURSE:    Patient is a 72 y.o. female who presents today with 2 weeks of cough and phlegm. She has a history of COPD and had quit smoking 2017 and started again when her husband died 2021. She has had pneumonia several times in the past. She presented to the hospital on 10/9/2022 with fatigue and cough. They started in her head and moved to her chest. CXR showed infiltrates bilaterally, right much greater than left. CT scan was ordered revealing bilateral ill defined patch airspace and ground glass opacities suspicious for multifocal pneumonia. On admission, COVID 19 positive, procalcitonin 0.28, WBC 15.5, lactic normal.    Discharged with supplemental oxygen, 2L nasal canula continuous, per respiratory evaluation. Received two full days of Unasyn and three full days of azithromycin, will be discharged with five days of Augmentin and four days of azithromycin for a total of a seven day course of antibiotics. She received 3 days of steroids, will be discharged with prednisone 40 mg daily for an additional 7 days for a 10 day course.    Patient was seen and evaluated- alert and oriented. She is happy to be returning home at this time. Reports shortness of breath has improved, denies chest pain, abdominal pain. She is able to tolerate oral intake. Patient is discharged in stable condition- all labs and imaging reviewed. No concerns at this time. All questions were answered prior to discharge.
next morning arm swelling, redness, itching all over, fever blisters, restlessness, noc sweats; self tx DPH; seen by MD 6APR; began steroid dose pack; joint pain & stiffness;To MD 11APR95 dx serum sickness
This spontaneous report was received from a health care student concerning a patient of unknown age and gender. It was reported that PNEUMOVAX23 (lot number, expiry date, dose and route unspecified) was exposed to 50 degrees Fahrenheit (F) for 10 days which was not supported. She stated that she was unsure if it was administered to any patients. No concomitant medications were reported. Additional information has been requested.
He has shingles on his face on the left side of his forehead. Dermatologist gave him acyclovir. Dermatologist diagnosed him with shingles.
She was in rehab for 6 weeks after twisting her ankle; Received second dose in the bone instead of the muscle; Technician who was administering the vaccine did not give her an alcohol swab, band-aid, or anything; This spontaneous case was reported by a consumer and describes the occurrence of JOINT INJURY (She was in rehab for 6 weeks after twisting her ankle), PRODUCT ADMINISTERED AT INAPPROPRIATE SITE (Received second dose in the bone instead of the muscle) and PRODUCT ADMINISTRATION ERROR (Technician who was administering the vaccine did not give her an alcohol swab, band-aid, or anything) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE for Hashimoto's disease.   On 22-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced JOINT INJURY (She was in rehab for 6 weeks after twisting her ankle), PRODUCT ADMINISTERED AT INAPPROPRIATE SITE (Received second dose in the bone instead of the muscle) and PRODUCT ADMINISTRATION ERROR (Technician who was administering the vaccine did not give her an  alcohol swab, band-aid, or anything). At the time of the report, JOINT INJURY (She was in rehab for 6 weeks after twisting her ankle) outcome was unknown and PRODUCT ADMINISTERED AT INAPPROPRIATE SITE (Received second dose in the bone instead of the muscle) and PRODUCT ADMINISTRATION ERROR (Technician who was administering the vaccine did not give her an  alcohol swab, band-aid, or anything) had resolved.            Patient reported that she didn't get a prescription for prednisone and that her symptoms were from when she was taken off of prednisone.  No treatment medication were provided.   Most recent FOLLOW-UP information incorporated above includes: On 16-Aug-2021: Follow-up received non-significant On 23-Aug-2021: Follow up document received on 23AUG2021 contains no new information.
Pt experienced an injection site reaction (right deltoid) characterized by redness, edematous, extremely warm to touch from distal tip of right clavical spreading to area just above right antecubital fossa.
6-8 hrs p/immun, child had unconsolable crying for around 2 hrs; Also slept for over 15hrs needing to be awakened for feedings; Normal sleeping time 8-10hrs;
Itchy, painful rash on rt side of chest. Dx?d w/a shingles on 2/11/2021
No adverse event/ No known pt adverse events; Indavertently administered improperly stored GARDASIL 9/ Temp excursion - vaccines given despite temp excursion; This spontaneous report was received from a licensed practical nurse (LPN) regarding to a 10-year-old male patient. The patient's concurrent conditions, pertinent medical history, concomitant therapies, drug reactions, and allergies were not provided.  On an unknown date, the patient was vaccinated with the first dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) (dose, formulation, anatomical location, route of administration, lot number and expiration date were not reported) for prophylaxis. On unknown dates, the patient was vaccinated with first, second, third and fourth doses of influenza vaccine (INFLUENZA) (doses, formulations, anatomical locations, routes of administration, lot numbers and expiry dates were not provided for all doses) for prophylaxis. On 05-NOV-2021, the patient was vaccinated intramuscularly, in his right deltoid, with an improperly stored (product storage error) second dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) pre-filled syringe lot number 1687290, with an expiration date of 06-SEP-2022 (dose was not reported) for prophylaxis and vaccinated intramuscularly, in his right deltoid, with the fifth dose of influenza vaccine (INFLUENZA) lot number: FT779, expiry date: 30-JUN-2022 (dose and formulation were not reported) for prophylaxis. There were no additional adverse event details. Administered dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) experienced the temperature excursion of 27.2 degrees Fahrenheit (F) and 49.8 F for 8 hours 30 minutes and 21 hours and 15 minutes respectively. There were no previous excursions reported. Temperature excursion details for influenza vaccine (INFLUENZA) were not provided. The improper storage was recorded by digital data logger.  This is one of nine reports received from the same reporter. ; Sender's Comments:  US-009507513-2202USA007811: US-009507513-2202USA007815: US-009507513-2202USA007816: US-009507513-2202USA007817: US-009507513-2202USA007818: US-009507513-2202USA007812: US-009507513-2202USA002574: US-009507513-2202USA007813:
When I spoke with patient she did not have any adverse events. She stated that she was feeling normal. Advised to watch for symptoms and reach out to the clinic if she had questions.
Child was given vaccines 1/8/07 and was febrile to 103, mottled and admitted to ICU. Baby has Hypoplastic left heart, on O2 N/O. 03/26/07-records received from facility for DOS 1/8-02/28/07 DC DX: Hypoaortic left heart syndrome. A-V fistula repair 1/18. Fever. Endocarditis. presented to ED with cyanosis and respiratory distress. Admitted for hypoxemia and febrile illness. Loose stools on date of admission. HX:Temp 103.5 in ED and pulse 180. Pulse Ox 73% with BB O2. Noted to be mottled with respitory distress. Seizures times three and results of A-V fistula.
Post giving hep a, hep b, and Td vaccines (approx 15 min) pt returned with complaint of sob, chest tightness and dizziness.
pfizer covid vaccine administered 5:15pm 5/20, at 5:30pm pt. experiencing  deep breathing and chest pains; called 911 dispatcher told me to give 4-81mg ablets; life squad arrived immediately; evaluated pt.; it was evaluated as an anxiety event.
On 12/15/00, employee was given monovalent measles vaccination for a non-reactive titer drawn as part of post offer physical. On 12/20/00, she came to employee health to report redness and hardness. Redness was approx. 8cm in diameter and induration of 40cm. No fever. Returned on 12/26/00 and area was larger. Recommended 600mg ibuprofen 3 X day and will recheck on 12/29/00.
Adacel started to leak while administering it; Adacel started to leak while administering it; Initial information received on 28-Aug-2019 and additional information received on 29-AUG-2019 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 52 years old female patient who received 0.5 mL dose of vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] but it started to leak while administering, lot U6103AA, expiry date: 25-10-2020 via intramuscular route in the left deltoid on 27-Aug-2019.  The patient's past vaccination(s) included adacel 10 or 15 years ago.  The patient's past medical history, medical treatment(s) and family history were not provided.  It was a case of vaccine underdose and syringe issue.  Final diagnosis was adacel started to leak while administering it and adacel started to leak while administering it.  Documents held by sender: none.
fever, chills, body aches, tachycardia, headache. started 4 hours after administration of vaccine
Fever that was at times as high as 103.2, but was well controlled with Tylenol every four hours. The fever went up and down and lasted for six days.
Small hive developed below area of injection of Proquad in about 5 min after injection. Benadryl given no respir sx in voice or swallowing lungs clear
injection site is currently bruised / bruise is a yellow/green color; very itchy rash on my injection arm; it did bleed at the injection; she could not move her right arm; injection site hurt; This case was reported by a consumer via call center representative and described the occurrence of itchy rash in a 52-year-old female patient who received Herpes zoster (Shingrix) (batch number 75P7G, expiry date 17th April 2022) for prophylaxis.   The patient's past medical history included anxiety disorder (had Anxiety Disorder) and hypersensitivity (had hypersensitivity to medications). Previously administered products included Tetanus shot with an associated reaction of injection site pain (had tetanus shot with pain during injection). Concurrent medical conditions included allergy.   On 9th July 2020, the patient received the 1st dose of Shingrix (intramuscular). On 9th July 2020, immediately after receiving Shingrix, the patient experienced injection site hemorrhage, injection site pain and injected limb mobility decreased. On 14th July 2020, the patient experienced itchy rash. On 15th July 2020, the patient experienced injection site bruising. The patient was treated with non-drug therapy (Ice Pack (No Medication)), ibuprofen and benadryl (nos) (Benadryl Cream). On an unknown date, the outcome of the itchy rash and injection site bruising were not recovered/not resolved and the outcome of the injection site hemorrhage was unknown and the outcome of the injection site pain and injected limb mobility decreased were recovered/resolved.   It was unknown if the reporter considered the itchy rash, injection site hemorrhage, injection site bruising, injection site pain and injected limb mobility decreased to be related to Shingrix.  Additional details were provided as follows: The age at the vaccination was not reported. The patient received dose of Shingrix in the right deltoid. The reporter stated that, the patient did not had more pain during injetion than the past immunization. The reporter stated that it did not hurt worse than a tetnus shot. The reporter stated that the patient had injection site bleeding and currently had injection site bruised. The bruise was a yellowor green color. The patient had injection site pain for 3 days and could not move right arm. On 14th July 2020, the patient had itchy rash on the right deltoid, but the rash was spreading and was about the size of her hand. the patient treated with icing and ibuprofen, and pain and immobility resolved. The patient treated with Benadryl cream for itchy rash.
Pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Pain at the injection site) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Pain at the injection site). At the time of the report, VACCINATION SITE PAIN (Pain at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported. No treatment medications provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up received on 14-JUL-2021 and contains no new significant information
Dizziness, headache, tiredness, insomnia, malaise occuring daily for hours at a time.
pt recvd vax & 3hrs post vax pt exp severe chills & nausea;these sx lasted 1 1/2 days;
Shortness of breath (3pm-8 pm), chest pain 3pm-8 pm), Headache (3pm- next morning), lightheadedness (3 pm-8 pm) Treatment: emergency room visit and observation for 4+ hours,  Benadryl, EKG, chest X-ray, 650 mg Tylenol Outcomes: improvement of all symptoms for the most part, some recurrence next day, but resolved after that.
The shot was given extremely high on the arm almost on the shoulder. Have had severe shoulder pain ever since, was put on predisone for 5 days, did not help. Went back to clinic and they pretty much told me they were not responsible. Started having high fever, aches and chills the same night I received the shot. that was October 10th and I am still in a lot of pain. Went to another Dr. and he put me on a z-pack for 6 days, still in pain severe, that was about 2 1/2 weeks ago.
Received the second dose of Moderna covid-19 vaccine on 28Apr2021; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the second dose of Moderna covid-19 vaccine on 28Apr2021) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the second dose of Moderna covid-19 vaccine on 28Apr2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the second dose of Moderna covid-19 vaccine on 28Apr2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported   No treatment medications provided by the reporter.  Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: follow up information received on 3-jun-2021 , it does not contain any new information.
Week of 3/22/21 Unprecedented IBS, upper right abdominal pain, lower right pelvic pain, muscle pain at injection site, axillary lymph node pain in left arm, mental "spaceyness".
Nausea and vomiting started at 5:45am Monday. Vomiting at least once per hour until a little after 7pm that day. Injection was in left arm but under arm on right side start hurting just a bit Monday afternoon. (I?m missing a couple of lymph nodes under right arm). I didn?t call PCP because I felt I would feel better. I was feeling better by Monday evening.
This spontaneous report as received from a registered nurse refers to a patient of unknown age with asplenia. On an unknown date the patient was vaccinated with PNEUMOVAX 23 (INJ 25/0.5 Y) (dose, lot and expiry date unknown). On an unknown date the patient developed severe arm swelling that looked cellulitis. The outcome of event was reported as recovered/resolved. The patient was seen in emergency room. Additional information has been requested.
Started with low fever - then awoke 07/15/2010 slightly hoarse with whooping sound with inhaling during crying / laughing.  No appetite. not sleeping well.  Advanced to 103 fever on 07/16 a.m., lethargy, some choking coughing with whooping during inhalation. Ibuprofen and acetaminophen given for fever and discomfort.  Sponge bath for fever.  Nebulized albuterol started 07/16 pm.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021 at 12:57 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 11-Jan-2021 at 12:57 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 79.20 for dose administered on 11-Jan-2021. No concomitant medications were reported. Batch number 041L20A underwent temperature excursion on 11-Jan-2021 with temperature 34 degrees Fahrenheit at 09:00 AM, and 35 degree Fahrenheit at 02:00 PM. This vial was moved to fridge on 08-Jan-2021 and beyond use date for the vial was reported as 07-Jan-2021. Product moved to clinic on 11-Jan-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour. No treatment medications were reported.
I experienced fever, tiredness, ear pain, teeth pain (3-4 teeth) and that prompted me to go to the ER. I initially thought it was a sinus infection but at the ER I was diagnosed with trigeminal neuralgia which causes chronic facial pain. I also went to the dentist and got X-Ray's done and the dentist did not see anything dental related.
This spontaneous report was received from an office manager and refers to 19 year old patient of unknown gender. There was no information about the patient's pertinent medical history and drug reactions or allergies. On 07-APR-2017, the patient was vaccinated with a pediatric dose of VAQTA (first dose) 25/0.5 (units were not provided) (lot # M047658 , expiration date: 20-OCT-2017, site and route of administration were not provided). No adverse effect was reported Additional information has been requested.
After 3-4 days of the first shot of Moderna, I feel chest pain  I have visited the provider last Saturday and this Monday. They asked me to report the side effects to you; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (After 3-4 days of the first shot of Moderna, I feel chest pain  I have visited the provider last Saturday and this Monday. They asked me to report the side effects to you) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history were reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CHEST PAIN (After 3-4 days of the first shot of Moderna, I feel chest pain  I have visited the provider last Saturday and this Monday. They asked me to report the side effects to you). At the time of the report, CHEST PAIN (After 3-4 days of the first shot of Moderna, I feel chest pain  I have visited the provider last Saturday and this Monday. They asked me to report the side effects to you) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant drug details were reported. No treatment details were reported. No lab data has been provided by the reporter.
After receiving her first dose of the Pfizer Covid-19 vaccine, patient complained of headache, dizziness and per patient was worried she would be experiencing & severe. EMS was called and medical took her for observation
Myalgia, Fever, CoughWheeze, Diarrhea, Chills, fatigue Narrative:
He had a seizure at 1:15 pm on Saturday. Body shaking; foaming at the mouth; bit his tongue; gurgling sounds.
Patient had already received two Pfizer vaccines in February.  She came here and got a Janssen.